Results 111 to 120 of about 231,458 (256)

HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies

, 2017
Key Points HDAC6 inhibition represents a novel strategy to improve the efficacy of anti-CD20 mAbs. HDAC6 inhibition increases CD20 levels by enhancing CD20 protein synthesis without affecting the gene expression.
Beata Pyrzynska, Piotr Zapala, Marta Karp, Nina Miazek, Lukas Frenzel, Michal Dwojak, Angelika Muchowicz, Magdalena Winiarska, Antoni Domagala, Agnieszka Graczyk-Jarzynka, Agnieszka Zagozdzon, Thorsten Zenz, Luca Laurenti, Malgorzata Firczuk, Elise Berthel, Dimitar G. Efremov, Nicole Dalla-Venezia, Dunja Baatout, Malgorzata Bobrowicz, Agata Malinowska, Mieszko Kozikowski, Magdalena Gabrysiak, Jakub Golab, Joanna Stachura, Kamil Bojarczuk, Mikolaj Slabicki, Agata Malenda, Joanna Barankiewicz, Krzysztof Giannopoulos, Marta Siernicka, Ewa Lech-Maranda, Abdessamad Zerrouqi, Jean-Jacques Diaz   +32 more
core   +1 more source

Trends and socio‐economic disparities in chronic lymphocytic leukaemia 2014–2022: An England‐wide cohort study from the UNCOVER group

British Journal of Haematology, EarlyView.
Summary To re‐evaluate chronic lymphocytic leukaemia (CLL) epidemiology in the era of modern therapy, data were extracted from the English National Cancer Registration Dataset (NCRD). A total of 34 427 consecutive diagnoses of CLL were recorded (2014–2022), the largest European dataset on record.
Temitope Erinfolami, Amelia Fisher, Indrani Karpha, Yeong Lim, Nurunnahar Akter, Toyyib Abdulkareem, Brogan Johnston, Catrin Tudur Smith, Hilary Lindsay, Shaun Bowden, Debbie Yates, Lelia Duley, Renata Walewska, Stella Williams, David Allsup, Nagesh Kalakonda, Mark Bishton, Andrew Pettitt, Nicolas Martinez‐Calle   +18 more
wiley   +1 more source

CD20 positivity in classical hodgkin\u27s lymphoma: diagnostic challenge or targeting opportunity. [PDF]

, 2009
BACKGROUND:It is now well established that Hodgkin cells are clonal B cells with a CD30 and CD15 phenotype. However, on immunohistochemistry, in our experience and the experience of others, CD20 positivity in an otherwise typical classical Hodgkin\u27s ...
Barakzai, Muhammad Abrar, Ahmed, Shahid
core  

Lymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy

, 2017
Objective To identify the most relevant antigens for monoclonal antibodies in lymphocytic infiltrates in non-systemic vasculitic neuropathy (NSVN).Background Current immunosuppressive treatment for NSVN is insufficient.
Wunderlich, Gilbert, Gilbert Wunderlich, Johannes Bleistein, Lehmann, Helmar Christoph, Helmar Christoph Lehmann, Deckert, Martina, Brunn, Anna, Martina Deckert, Bleistein, Johannes, Fink, Gereon Rudolf, Christian Schneider, Schneider, Christian, Anna Brunn, Gereon R Fink   +13 more
core   +1 more source

P106 | Cd20 positive multiple myeloma: is it a different entity?

Haematologica
Introduction. Expression of CD20 antigen is generally negative in patients (pts) with multiple myeloma (MM). However, a small number of MM pts (15-20%) can show CD20 positivity on neoplastic plasma cells (PC).
Monica Poscente
doaj  

CAR‐HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, EarlyView.
High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar, David Tucker, Tae Min Kim, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Manjusha Namuduri, Aafia Chaudhry, Stefano Luminari   +9 more
wiley   +1 more source

Caracterización inmunofenotípica de la leucemia linfoide crónica-B Immunophenotypical characterization of B-cell chronic lymphocytic leukemia

Revista Cubana de Hematología, Inmunología y Hemoterapia, 2007
Se realizó la caracterización inmunofenotípica de 115 pacientes con leucemia linfoide crónica de fenotipo B, de células procedentes de médula ósea y sangre periférica mediante un ultramicrométodo inmunocitoquímico en el Instituto de Hematología e ...
Miriam Sánchez Segura, Vianed Marsán Suárez, Bertha Beatriz Socarrás Ferrer, Yanelkys Cos Padrón, René Rivero Jiménez, Mercedes Martínez Machado, Isabel María Torres Leyva, Lázaro O del Valle Pérez, Porfirio Hernández Ramírez, Consuelo Macías Abraham   +9 more
doaj  

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients

, 2018
Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects in reduction of disease activity in multiple sclerosis (MS) patients and has recently been approved for the treatment of patients with relapsing MS (RMS) and primary ...
Thais Langer Jacobus, Franz Felix Konen, Lars H. Müschen, Martin W. Hümmert, Kurt-Wolfram Sühs, Nora Möhn, Sascha Alvermann, Jonas Ahlbrecht, Stefan Gingele, Roland Jacobs, Lars H. Müschen, Reinhold E. Schmidt, Thomas Skripuletz, Martin W. Hümmert, Thais Langer Jacobus, Franz Felix Konen, Lena Bönig, Martin Stangel, Reinhold E. Schmidt, Philipp Schwenkenbecher   +19 more
core   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

CD20 inhibitors : rituximab

, 2016
The CD20 inhibitors are protein constructs which bind and inactivate CD20. They are members of a group of drugs active in rheumatoid arthritis known as biological disease-modifying antirheumatic drugs (bDMARDs).
Mahler, Stephen M., Pile, Kevin (R17082), Stephen M. Mahler, Garry G. Graham, Kevin D. Pile, Graham, Garry G.   +5 more
core   +1 more source